Literature DB >> 33894556

Immunohistochemical expression and significance of SATB2 protein in colorectal cancer.

Veronika Cígerová1, Marian Adamkov2, Slávka Drahošová3, Marián Grendár4.   

Abstract

In this study we evaluated the expression of SATB2 protein in colorectal cancer (CRC) and its association with microsatellite instability (MSI) status, inflammation and hypoxia. Immunohistochemical SATB2 expression was observed in 111 CRC samples. We assessed the correlation between SATB2 expression and clinico-morphological parameters, MSI, COX-2 and HIF-1α expression. SATB2 was noticed in 92.8% CRC. We observed nuclear staining with predominantly strong immunoreaction intensity (67.6%) and percentage of SATB-2 positive cells in more than 50% of cells (87.4%). The statistically significant associations were recorded between high SATB2 expression and low grade, negative lymph nodes and negative vascular invasion. Statistical analysis confirmed a significant correlation between SATB2 expression and microsatellite stability, tendency to correlate with COX-2 and no significant correlation with HIF-1α. SATB2 is overexpressed in CRC and its high expression is a marker of good prognosis. Moreover, SATB2 expression is significantly associated with microsatellite stability, there is tendency to correlate with pro-inflammatory COX-2 and there is no association with hypoxia.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Colorectal cancer; Hypoxia; Inflammation; Microsatellite instability; SATB2

Year:  2021        PMID: 33894556     DOI: 10.1016/j.anndiagpath.2021.151731

Source DB:  PubMed          Journal:  Ann Diagn Pathol        ISSN: 1092-9134            Impact factor:   2.090


  1 in total

1.  Loss of SATB2 Occurs More Frequently Than CDX2 Loss in Colorectal Carcinoma and Identifies Particularly Aggressive Cancers in High-Risk Subgroups.

Authors:  Maxime Schmitt; Miguel Silva; Björn Konukiewitz; Corinna Lang; Katja Steiger; Kathrin Halfter; Jutta Engel; Paul Jank; Nicole Pfarr; Dirk Wilhelm; Sebastian Foersch; Carsten Denkert; Markus Tschurtschenthaler; Wilko Weichert; Moritz Jesinghaus
Journal:  Cancers (Basel)       Date:  2021-12-07       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.